Summit Global Investments Purchases New Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Summit Global Investments acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 4th quarter, Holdings Channel reports. The firm acquired 14,027 shares of the specialty pharmaceutical company’s stock, valued at approximately $773,000.

Other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its stake in shares of ANI Pharmaceuticals by 93.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 248 shares during the last quarter. BluePath Capital Management LLC bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth about $34,000. Pacer Advisors Inc. acquired a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at about $41,000. Robeco Institutional Asset Management B.V. bought a new position in shares of ANI Pharmaceuticals during the third quarter worth about $189,000. Finally, C M Bidwell & Associates Ltd. grew its stake in ANI Pharmaceuticals by 398.6% in the third quarter. C M Bidwell & Associates Ltd. now owns 3,266 shares of the specialty pharmaceutical company’s stock worth $190,000 after purchasing an additional 2,611 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Truist Financial increased their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Capital One Financial started coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective on the stock. HC Wainwright boosted their target price on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Finally, Guggenheim reissued a “buy” rating and set a $77.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $80.00.

ANI Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ ANIP opened at $67.25 on Friday. ANI Pharmaceuticals, Inc. has a 12-month low of $37.64 and a 12-month high of $70.81. The company has a market cap of $1.42 billion, a price-to-earnings ratio of 80.06 and a beta of 0.80. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66. The stock’s 50 day simple moving average is $66.58 and its 200 day simple moving average is $59.17.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $131.65 million for the quarter, compared to analysts’ expectations of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 7,414 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $66.33, for a total value of $491,770.62. Following the completion of the transaction, the chief operating officer now owns 825,206 shares in the company, valued at approximately $54,735,913.98. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Nikhil Lalwani sold 28,965 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total value of $1,897,786.80. Following the completion of the transaction, the chief executive officer now owns 444,981 shares of the company’s stock, valued at $29,155,155.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Muthusamy Shanmugam sold 7,414 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $66.33, for a total value of $491,770.62. Following the transaction, the chief operating officer now directly owns 825,206 shares in the company, valued at $54,735,913.98. The disclosure for this sale can be found here. Insiders have sold a total of 176,803 shares of company stock worth $11,695,866 in the last ninety days. 12.70% of the stock is owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.